Letter: ozanimod and latent tuberculosis—authors' reply-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Letter: ozanimod and latent tuberculosis—authors' reply

Published:2023-01-15 Issue:3 Volume:57 Page:355-356
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Zhang Eva¹²,Christensen Britt¹³^ORCID

Affiliation:

1. Gastroenterology Department, The Royal Melbourne Hospital Melbourne Australia

2. Macquarie University Sydney Australia

3. Department of Medicine University of Melbourne Melbourne Australia

Abstract

LINKED CONTENTThis article is linked to Fehily et al papers. To view these articles, visit https://doi.org/10.1111/apt.16952 and https://doi.org/10.1111/apt.17311

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17345

Reference8 articles.

1. Letter: ozanimod and latent tuberculosis;Alaskar D;Aliment Pharmacol Ther,2023

2. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management

3. Everstar therapeutics limited.A phase 3 study of Etrasimod in subjects with moderately to severely active ulcerative colitis. ClinicalTrials.gov NCT04176588.2019[cited 2022 Nov 28]. Available from:https://clinicaltrials.gov/ct2/show/NCT04176588

4. Activation‐regulated expression and chemotactic function of sphingosine 1‐phosphate receptors in mouse splenic T cells

5. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP